Trial Profile
Phase-II Trial to Assess the Efficacy and Safety of Lenalidomide in Addition to 5-Azacitidine and Donor Lymphocyte Infusions (DLI) for the Treatment of Patients With MDS, CMML or AML Who Relapse After Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms AZALENA
- 14 Dec 2021 Final results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 26 May 2020 Status changed from active, no longer recruiting to completed.
- 29 Jan 2019 Planned End Date changed from 1 Sep 2020 to 30 Sep 2020.